Select publications

Benoit RM et al. A comparison of complications between ultrasound-guided prostate brachytherapy and open prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;47(4):909-13. Abstract

Chenven ES et al. Evaluation of prostate volume by transrectal ultrasonography for use in a brachytherapy program. Urology 2001;58(5):752-5. Abstract

Critz FA, et al. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 2000;163(4):1085-9. Abstract

Critz FA. Time to achieve a prostate specific antigen nadir of 0.2 ng./ml. after simultaneous irradiation for prostate cancer. J Urol 2002;168(6):2434-8. Abstract

D’Amico AV. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology 2002;60(3 Suppl 1):32-7. Abstract

Das P et al. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int J Radiat Oncol Biol Phys 2002;54(3):698-702. Abstract

Epstein J. et al. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1C disease. J of Urol 2001;166:1688-691. Abstract.

Grado GL. Techniques to achieve optimal seed placement in salvage and primary brachytherapy for prostate cancer. Tech Urol 2000;6(2):157-65. Abstract

Grimm PD et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001;1;51(1):31-40. Abstract

Hanlon AL et al. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys 2001;50(4):845-9. Abstract

Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002;52(3):154-79. Abstract

Holmes DR 3rd et al. 3D localization of implanted radioactive sources in the prostate using transurethral ultrasound. Stud Health Technol Inform 2001;81:199-205. Abstract

Lee LN et al. Role of hormonal therapy in the management of intermediate-to-high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002;52(2):444-52. Abstract.

Martinez AA et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002;53(2):316-27. Abstract

Mcleod DG. Emerging role of adjuvant hormonal therapy. Urology 2002;60(3Suppl 1):13-20. Abstract

Rosser CJ et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 2002;168(5):2001-5. Abstract

Sharkey J et al. Evolution of techniques for ultrasound-guided palladium 103 brachytherapy in 950 patients with prostate cancer. Tech Urol 2000;6(2):128-34. Abstract

Stock, RG. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer. Brachytherapy 2002;1:2-10. No abstract available.

Stock RG et al. Intraoperative dosimetric representation of the real-time ultrasound-guided prostate implant. Tech Urol 2000;6(2):95-8. Abstract

Stock RG et al. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer 1996;77(11):2386-92. Abstract

Stone NN et al. Biopsy results after real-time ultrasound-guided transperineal implants for stage T1-T2 prostate cancer. J Endourol 2000;14(4):375-80. Abstract

Stone N et al. Early and late effects of neoadjuvant hormonal therapy on prostate-specific antigen and prostate volume following permanent seed implantation for prostate carcinoma. Intl. Int J Radiat Oncol Biol Phys 2001;51(3) Suppl.1: 316. Abstract

Stone NN, Stock RG. Brachytherapy for prostate cancer: Real-time three-dimensional interactive seed implantation. Tech Urol 1995;1(2):72-80. Abstract .

Stone NN, Stock RG. Permanent seed implantation for localized adenocarcinoma of the prostate. Curr Urol Rep 2002;3(3):201-6. Abstract

Vicini FA et al. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation. Tech Urol 2000;6(2):135-45. Abstract

Zelefsky MJ et al. Improved conformality and decreased toxicity with intraoperative computeroptimized transperineal ultrasound-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;55(4):956-63. Abstract

Home

Editor’s Note

Mark S Soloway, MD
    - Select publications

Richard Stock, MD
    - Select publications

Mitchell Benson, MD
    - Select publications

Editor's Office